Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Icotinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EVIDENCE
- Sponsors Betta Pharmaceuticals Co Ltd
- 08 Feb 2018 Planned End Date changed from 1 Nov 2021 to 1 Dec 2022.
- 08 Feb 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2020.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology